BioWorld

April 19, 2004

Immunicon Raises $48M In IPO; Lower Pricings Trend Continues

Following a recent trend of lower-than-expected pricings, Immunicon Corp. stepped up to the initial public offering plate on Friday, raising a total of $48 million. (BioWorld Today) Read More

Cytogen Brings In $26M To Increase Sales Force Size

Panel Discusses Potential Ways To Improve FDA Approval Cycle

Hybridon Signs Deal To Raise $11.8M For Cancer, HIV Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...